Panobinostat-A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report

Area of Science:

• Oncology
• Cancer Research

Background:

• Ewing sarcoma (ES) is a rare primary bone cancer with limited treatment options.
• Relapsed ES has a poor prognosis, with a 5-year survival rate of only 13%.
• Histone deacetylase (HDAC) inhibitors are being investigated as potential cancer therapies.

Observation:

• A patient with inoperable, progressive lung metastases from ES was treated with the HDAC inhibitor panobinostat.
• Treatment with panobinostat was administered for 18 months.

Findings:

• During the 18-month treatment period, no new metastatic lesions were observed.
• The patient's disease eventually progressed, leading to treatment cessation.

Implications:

• This case suggests that HDAC inhibitors like panobinostat may have a role in managing advanced or relapsed Ewing sarcoma.
• Further clinical evaluation of HDAC inhibitors, potentially in combination with chemotherapy or guided by biomarkers, is warranted to improve therapeutic outcomes in ES.